Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

Eva Havrdova; Douglas L. Arnold; Jeffrey A. Cohen; Hans-Peter Hartung; Edward J. Fox; Gavin Giovannoni; Sven Schippling; Krzysztof W. Selmaj; Anthony Traboulsee; D. Alastair S. Compston; David H. Margolin; Karthinathan Thangavelu; Claudio E. Rodriguez; Darlene Jody; Richard J. Hogan; Panos Xenopoulos; Michael A. Panzara; CARE-MS I CAMMS03409 Investigators; Raymond Hupperts; Alasdair J. Coles

doi:10.1212/WNL.0000000000004313

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

Eva Havrdova^*, Douglas L. Arnold, Jeffrey A. Cohen, Hans-Peter Hartung, Edward J. Fox, Gavin Giovannoni, Sven Schippling, Krzysztof W. Selmaj, Anthony Traboulsee, D. Alastair S. Compston, David H. Margolin, Karthinathan Thangavelu, Claudio E. Rodriguez, Darlene Jody, Richard J. Hogan, Panos Xenopoulos, Michael A. Panzara, CARE-MS I CAMMS03409 Investigators, Raymond Hupperts, Alasdair J. Coles

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	1107-1116
Number of pages	10
Journal	Neurology
Volume	89
Issue number	11
DOIs	https://doi.org/10.1212/WNL.0000000000004313
Publication status	Published - 12 Sep 2017

Keywords

MULTIPLE-SCLEROSIS PATIENTS
CONTROLLED PHASE-3 TRIAL
LONG-TERM DISABILITY
BRAIN ATROPHY
INTERFERON-BETA

Access to Document

10.1212/WNL.0000000000004313

Cite this

Havrdova, E., Arnold, D. L., Cohen, J. A., Hartung, H-P., Fox, E. J., Giovannoni, G., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., Margolin, D. H., Thangavelu, K., Rodriguez, C. E., Jody, D., Hogan, R. J., Xenopoulos, P., Panzara, M. A., CARE-MS I CAMMS03409 Investigators, Hupperts, R., & Coles, A. J. (2017). Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology, 89(11), 1107-1116. https://doi.org/10.1212/WNL.0000000000004313

Havrdova, Eva ; Arnold, Douglas L. ; Cohen, Jeffrey A. ; Hartung, Hans-Peter ; Fox, Edward J. ; Giovannoni, Gavin ; Schippling, Sven ; Selmaj, Krzysztof W. ; Traboulsee, Anthony ; Compston, D. Alastair S. ; Margolin, David H. ; Thangavelu, Karthinathan ; Rodriguez, Claudio E. ; Jody, Darlene ; Hogan, Richard J. ; Xenopoulos, Panos ; Panzara, Michael A. ; CARE-MS I CAMMS03409 Investigators ; Hupperts, Raymond ; Coles, Alasdair J. / Alemtuzumab CARE-MS I 5-year follow-up : Durable efficacy in the absence of continuous MS therapy. In: Neurology. 2017 ; Vol. 89, No. 11. pp. 1107-1116.

@article{1a48f4556aec491cb0b35478fff58de5,

title = "Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy",

keywords = "MULTIPLE-SCLEROSIS PATIENTS, CONTROLLED PHASE-3 TRIAL, LONG-TERM DISABILITY, BRAIN ATROPHY, INTERFERON-BETA",

author = "Eva Havrdova and Arnold, {Douglas L.} and Cohen, {Jeffrey A.} and Hans-Peter Hartung and Fox, {Edward J.} and Gavin Giovannoni and Sven Schippling and Selmaj, {Krzysztof W.} and Anthony Traboulsee and Compston, {D. Alastair S.} and Margolin, {David H.} and Karthinathan Thangavelu and Rodriguez, {Claudio E.} and Darlene Jody and Hogan, {Richard J.} and Panos Xenopoulos and Panzara, {Michael A.} and {CARE-MS I CAMMS03409 Investigators} and Raymond Hupperts and Coles, {Alasdair J.}",

year = "2017",

month = sep,

day = "12",

doi = "10.1212/WNL.0000000000004313",

language = "English",

volume = "89",

pages = "1107--1116",

journal = "Neurology",

issn = "0028-3878",

publisher = "LIPPINCOTT WILLIAMS & WILKINS",

number = "11",

}

Havrdova, E, Arnold, DL, Cohen, JA, Hartung, H-P, Fox, EJ, Giovannoni, G, Schippling, S, Selmaj, KW, Traboulsee, A, Compston, DAS, Margolin, DH, Thangavelu, K, Rodriguez, CE, Jody, D, Hogan, RJ, Xenopoulos, P, Panzara, MA, CARE-MS I CAMMS03409 Investigators, Hupperts, R & Coles, AJ 2017, 'Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy', Neurology, vol. 89, no. 11, pp. 1107-1116. https://doi.org/10.1212/WNL.0000000000004313

Alemtuzumab CARE-MS I 5-year follow-up : Durable efficacy in the absence of continuous MS therapy. / Havrdova, Eva; Arnold, Douglas L.; Cohen, Jeffrey A.; Hartung, Hans-Peter; Fox, Edward J.; Giovannoni, Gavin; Schippling, Sven; Selmaj, Krzysztof W.; Traboulsee, Anthony; Compston, D. Alastair S.; Margolin, David H.; Thangavelu, Karthinathan; Rodriguez, Claudio E.; Jody, Darlene; Hogan, Richard J.; Xenopoulos, Panos; Panzara, Michael A.; CARE-MS I CAMMS03409 Investigators ; Hupperts, Raymond; Coles, Alasdair J.

In: Neurology, Vol. 89, No. 11, 12.09.2017, p. 1107-1116.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Alemtuzumab CARE-MS I 5-year follow-up

T2 - Durable efficacy in the absence of continuous MS therapy

AU - Havrdova, Eva

AU - Arnold, Douglas L.

AU - Cohen, Jeffrey A.

AU - Hartung, Hans-Peter

AU - Fox, Edward J.

AU - Giovannoni, Gavin

AU - Schippling, Sven

AU - Selmaj, Krzysztof W.

AU - Traboulsee, Anthony

AU - Compston, D. Alastair S.

AU - Margolin, David H.

AU - Thangavelu, Karthinathan

AU - Rodriguez, Claudio E.

AU - Jody, Darlene

AU - Hogan, Richard J.

AU - Xenopoulos, Panos

AU - Panzara, Michael A.

AU - CARE-MS I CAMMS03409 Investigators

AU - Hupperts, Raymond

AU - Coles, Alasdair J.

PY - 2017/9/12

Y1 - 2017/9/12

KW - MULTIPLE-SCLEROSIS PATIENTS

KW - CONTROLLED PHASE-3 TRIAL

KW - LONG-TERM DISABILITY

KW - BRAIN ATROPHY

KW - INTERFERON-BETA

U2 - 10.1212/WNL.0000000000004313

DO - 10.1212/WNL.0000000000004313

M3 - Article

C2 - 28835401

VL - 89

SP - 1107

EP - 1116

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 11

ER -